Treatment of the Cerebral Manifestations of Arteriosclerosis with Cyclandelate

Young, John; Hall, Peter; Blakemore, Colin

doi:10.1192/bjp.124.2.177

Cited by 19 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was observed, however, that the decline was greater during the placebo phase than during the cyclandelate phase. No such decline during the course of the trial was noted in the present study, possibly because the patients in the present study began at a lower pretrial level than in the Young et al 15 study. Patients in that study actually began with an "average" IQ.…”

Section: Discussioncontrasting

confidence: 60%

Effect of Cyclandelate on Dementia

Westreich

Alter

Lundgren

1975

Stroke

View full text Add to dashboard Cite

Abstract:Effect of Cyclandelate on Dementia• Cyclandelate, a vasodilator, was administered to 24 patients with dementia. The dementia in these patients was presumed to be due to cerebral ischemia caused by atherosclerosis in cerebral vessels after other possible causes were ruled out. In a double-blind, cross-over study, patients received 200 mg of cyclandelate four times daily for six weeks and a placebo for six weeks. Six psychological tests, which reflect various aspects of higher cortical ability, were used to evaluate the effect of cyclandelate on the dementia. Cyclandelate was found to be no more effective than placebo in improving higher cortical function in these demented patients.

show abstract

Section: Discussioncontrasting

confidence: 60%

Effect of Cyclandelate on Dementia

Westreich

Alter

Lundgren

1975

Stroke

View full text Add to dashboard Cite

show abstract

“…The clinical efficacy, unfortunately, has not been documented so clearly. Although several investigators have reported positive results (6–9), others have reported equivocal (10) or negative results (11). Nevertheless, it is apparent that in the past vasodilators have too often been prescribed indiscriminately, without proper selection of patients.…”

mentioning

confidence: 99%

“…The positive effect of cyclandelate on the attributes of impairment of recent memory, mood depression, irritability, hostility, indifference to surroundings and anxiety was significantly superior to that of placebo as early as the eighth week of treatment ( Table 2). (6)(7)(8)(9), others have reported equivocal (10) or negative results (11). Nevertheless, it is apparent that in the past vasodilators have too often been prescribed indiscriminately, without proper selection of patients.…”

mentioning

confidence: 99%

Cyclandelate in the Treatment of Senile Mental Changes: A Double‐Blind Evaluation

Rao¹,

Georgiev²,

Paul³

et al. 1977

J American Geriatrics Society

View full text Add to dashboard Cite

The treatment of cerebrovascular insufficiency and its many symptoms in the ever-increasing numbers of the aged, is of major concern to physicians engaged in such care. Despite past skepticism as to the degree of efficacy of cerebral vasodilators, there is renewed interest in this form of therapy. Our investigation was designed to assess the effectiveness of cyclandelate, under strict double-blind conditions, in 58 geriatric patients. The cyclandelate and placebo groups (32 and 26 patients respectively) received either 1,600 mg/day of cyclandelate in fractional doses, or identical-appearing placebo capsules--over a period of 12 weeks. During the initial examination and every four weeks thereafter, patients were assessed for possible changes in vital signs and for evidence of adverse reactions. In addition, the Sandoz Clinical Assessment-Geriatric (SCAG) and the Nurses Observation Scale for Inpatient Evaluation (NOSIE) were completed, with particular attention to symptom clusters. A final global assessment was made in which the physician rated patients according to their overall clinical condition. The results of our study and analysis indicate that cyclandelate is a safe and effective agent for treating certain symptoms of senility in properly selected patients, provided the therapy is carried on for at least eight weeks and, if indicated, for a longer period. Clinical evidence suggests that the prudent use of this drug may definitely delay deterioration.

show abstract

“…Cyclandelate has been used to treat patients with symptoms believed to be caused by cerebrovascular insufficiency, in addition to its more traditional use in treating various peripheral vascular disorders. Earlier studies of this drug predominantly evaluated its use in treating cerebral symptoms and showed that cyclandelate may offer improvement or delay in deterioration of certain symptoms of senility 6–10 . On the basis of these findings, researchers studied the drug's effects on other potential cerebrovascular symptoms: tinnitus, vertigo, and blurred vision.…”

mentioning

confidence: 99%

Cyclandelate in the Management of Tinnitus: A Randomized, Placebo‐Controlled Study

Hester

Theilman

Green

et al. 1998

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Cyclandelate is a vasodilating agent that, like papaverine, acts directly on the smooth muscles of blood vessels. The drug has been used primarily as an adjunctive treatment for various peripheral vascular diseases; some studies advocate its use for treating ischemic cerebrovascular disease. Early nonrandomized and uncontrolled studies suggest that cyclandelate is efficacious in treating tinnitus. Recent personal communications regarding cyclandelate's effectiveness in treating tinnitus prompted this study. Fifty-nine adult patients with constant tinnitus for more than 1 year were randomly selected for this prospective, placebo-controlled, double-blind study with a treatment period of 3 months. Audiometric testing with tinnitus pitch and loudness matching was performed before initiation of treatment and at the end of treatment, and frequent questionnaire evaluations were performed during the treatment period. Four patients in the cyclandelate group and three in the placebo group reported a subjective reduction in the loudness of their tinnitus. Audiologic testing before and after treatment showed no significant changes in tinnitus pitch or loudness. Although cyclandelate treatment was beneficial for some patients and the decrease in subjective loudness scoring was significant for the cyclandelate group, the impact of its effect did not appear to warrant its continued use by those patients. A significant percentage of patients could not tolerate the drug because of side effects.

show abstract

Treatment of the Cerebral Manifestations of Arteriosclerosis with Cyclandelate

Cited by 19 publications

References 6 publications

Effect of Cyclandelate on Dementia

Effect of Cyclandelate on Dementia

Cyclandelate in the Treatment of Senile Mental Changes: A Double‐Blind Evaluation

Cyclandelate in the Management of Tinnitus: A Randomized, Placebo‐Controlled Study

Contact Info

Product

Resources

About